{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:12:53Z","timestamp":1778343173831,"version":"3.51.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/md.0000000000002402","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T18:40:24Z","timestamp":1451414424000},"page":"e2402","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of HE4, CA125, and ROMA Diagnostic Accuracy"],"prefix":"10.1097","volume":"94","author":[{"given":"Pengjun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qishui","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-44-20210309","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R2-44-20210309","first-page":"10","article-title":"Report of incidence and mortality in China cancer registries, 2009","volume":"25","author":"Chen","year":"2013","journal-title":"Chin J Cancer Res"},{"key":"R3-44-20210309","first-page":"617","article-title":"An analysis of incidence and mortality for ovarian cancer in China, 2009","volume":"22","author":"Yang","year":"2013","journal-title":"China Cancer"},{"key":"R4-44-20210309","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"key":"R5-44-20210309","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/IGC.0b013e318263efa2","article-title":"Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis","volume":"22","author":"Wu","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"R6-44-20210309","doi-asserted-by":"crossref","first-page":"200s","DOI":"10.1200\/JCO.2003.01.068","article-title":"Status of tumor markers in ovarian cancer screening","volume":"21","author":"Bast","year":"2003","journal-title":"J Clin Oncol"},{"key":"R7-44-20210309","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res"},{"key":"R8-44-20210309","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13048-015-0201-z","article-title":"Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women","volume":"8","author":"Tian","year":"2015","journal-title":"J Ovarian Res"},{"key":"R9-44-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum Reprod"},{"key":"R10-44-20210309","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R11-44-20210309","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","article-title":"Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases","volume":"57","author":"Escudero","year":"2011","journal-title":"Clin Chem"},{"key":"R12-44-20210309","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm","volume":"104","author":"Van Gorp","year":"2011","journal-title":"Br J Cancer"},{"key":"R13-44-20210309","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R14-44-20210309","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"Ferraro","year":"2013","journal-title":"J Clin Pathol"},{"key":"R15-44-20210309","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejogrb.2012.10.036","article-title":"Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis","volume":"167","author":"Lin","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R16-44-20210309","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13277-012-0440-1","article-title":"An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions","volume":"33","author":"Macuks","year":"2012","journal-title":"Tumour Biol"},{"key":"R17-44-20210309","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1710-1492-9-42","article-title":"Threshold for basophil activation test positivity in neuromuscular blocking agents hypersensitivity reactions","volume":"9","author":"Hagau","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R18-44-20210309","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/sim.3859","article-title":"Evaluating diagnostic tests: the area under the ROC curve and the balance of errors","volume":"29","author":"Hand","year":"2010","journal-title":"Stat Med"},{"key":"R20-44-20210309","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1046\/j.1469-0705.2000.00287.x","article-title":"Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group","volume":"16","author":"Timmerman","year":"2000","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R21-44-20210309","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2012.11.026","article-title":"Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome","volume":"128","author":"Sandri","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R22-44-20210309","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1471-0528.1989.tb03341.x","article-title":"Revised FIGO staging for gynaecological cancer","volume":"96","author":"Shepherd","year":"1989","journal-title":"Br J Obstet Gynaecol"},{"key":"R23-44-20210309","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R24-44-20210309","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"R25-44-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536867X0900900101","article-title":"Estimation and comparison of receiver operating characteristic curves","volume":"9","author":"Pepe","year":"2009","journal-title":"Stata J"},{"key":"R26-44-20210309","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/17520363.1.4.513","article-title":"CA125 in ovarian cancer","volume":"1","author":"Scholler","year":"2007","journal-title":"Biomark Med"},{"key":"R27-44-20210309","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ajog.2011.05.017","article-title":"Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women","volume":"205","author":"Holcomb","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"R28-44-20210309","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajog.2011.12.029","article-title":"Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders","volume":"206","author":"Moore","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R29-44-20210309","first-page":"4137","article-title":"HE4 and ROMA index in Czech postmenopausal women","volume":"32","author":"Novotny","year":"2012","journal-title":"Anticancer Res"},{"key":"R30-44-20210309","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","article-title":"The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass","volume":"23","author":"Montagnana","year":"2009","journal-title":"J Clin Lab Anal"},{"key":"R31-44-20210309","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2407-12-258","article-title":"Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis","volume":"12","author":"Li","year":"2012","journal-title":"BMC Cancer"},{"key":"R32-44-20210309","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2012.09.034","article-title":"The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass","volume":"128","author":"Chan","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R33-44-20210309","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/IGC.0b013e318249bee7","article-title":"Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease","volume":"22","author":"Zheng","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"R34-44-20210309","doi-asserted-by":"crossref","first-page":"437","DOI":"10.6061\/clinics\/2012(05)06","article-title":"A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses","volume":"67","author":"Anton","year":"2012","journal-title":"Clinics"},{"key":"R35-44-20210309","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajog.2011.12.028","article-title":"Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age","volume":"206","author":"Moore","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R36-44-20210309","first-page":"4779","article-title":"HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer","volume":"30","author":"Kamei","year":"2010","journal-title":"Anticancer Res"},{"key":"R37-44-20210309","first-page":"164","article-title":"The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure","volume":"1","author":"de Boer","year":"2013","journal-title":"JACC"},{"key":"R38-44-20210309","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13277-013-1190-4","article-title":"A critical review on HE4 performance in endometrial cancer: where are we now?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol"},{"key":"R39-44-20210309","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1007\/s13277-014-1943-8","article-title":"Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol"},{"key":"R40-44-20210309","first-page":"35","article-title":"Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders","volume":"438C","author":"Kappelmayer","year":"2014","journal-title":"Clin Chim Acta"},{"key":"R41-44-20210309","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3233\/CBM-140399","article-title":"Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer","volume":"14","author":"Lou","year":"2014","journal-title":"Cancer Biomark"},{"key":"R42-44-20210309","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nm.2989","article-title":"Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis","volume":"19","author":"LeBleu","year":"2013","journal-title":"Nat Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000002402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T13:04:21Z","timestamp":1718283861000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201512280-00044"}},"subtitle":["A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer"],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":41,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002402","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}